The FDA has approved tofacitinib (Xeljanz, Pfizer) for the treatment of patients with moderate to severe ulcerative colitis.
The drug, the first Janus kinase (JAK) inhibitor to reach the market, is already available for the treatment of adults with moderate to severe rheumatoid arthritis. For UC, the regimen is 10 mg twice-daily for at least eight weeks, followed by 5 mg twice daily or 10 mg twice daily.
“With the FDA approval of Xeljanz, adults living with moderately to severely active
MAY 30, 2018